TABLE 4.
Relapse rates assessed 3 months after treatment completion in experiment 4
| Treatment with BDQ+PZA plus the indicated drug(s) (dose of PA-824 or TBA-354 [mg/kg]) | Proportion (no./total no. [%]) of mice relapsing after treatment for: |
|||
|---|---|---|---|---|
| 3 wk | 4 wk | 6 wk | 8 wk | |
| CFZ | 14/14 (100) | 13/15 (87)a | 5/15 (33) | |
| CFZ+PA-824 (50) | ND | 13/14 (93) | 14/15 (93)b | |
| CFZ+TBA-354 (25) | 15/15 (100) | 15/15 (100) | 9/15 (60) | |
| CFZ+TBA-354 (50) | 14/14 (100) | 14/15 (93) | ||
| CFZ+PNU | 15/15 (100) | 13/15 (87) | ||
| PNU | ND | 15/15 (100) | 14/15 (93) | 4/15 (27) |
| PNU+PA-824 (50) | ND | 10/15 (67)c | 1/15 (7)a | 0/15 (0) |
| PNU+TBA-354 (25) | ND | 7/15 (47)d | 0/15 (0)a | |
| PNU+TBA-354 (50) | 15/15 (100) | 6/15 (40)e | 0/15 (0)a | |
a
P < 0.0001 versus BDQ+PZA+PNU.
b
P = 0.002 versus BDQ+PZA+CFZ.
c
P = 0.04 versus BDQ+PZA+PNU.
d
P = 0.002 versus BDQ+PZA+PNU.
e
P = 0.0007 versus BDQ+PZA+PNU.